Third Harmonic Bio (Third Harmonic Bio) Capex-to-Operating-Income : 0.00 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Third Harmonic Bio Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Third Harmonic Bio's Capital Expenditure for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-11.29 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.

Third Harmonic Bio Capex-to-Operating-Income Historical Data

The historical data trend for Third Harmonic Bio's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Third Harmonic Bio Capex-to-Operating-Income Chart

Third Harmonic Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Capex-to-Operating-Income

Third Harmonic Bio Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capex-to-Operating-Income	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Third Harmonic Bio's Capex-to-Operating-Income

For the Biotechnology subindustry, Third Harmonic Bio's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Third Harmonic Bio's Capex-to-Operating-Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Third Harmonic Bio's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Third Harmonic Bio's Capex-to-Operating-Income falls into.

Third Harmonic Bio Capex-to-Operating-Income Calculation

Third Harmonic Bio's Capex-to-Operating-Income for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (-0.169)	/	-43.954
	=	N/A

Third Harmonic Bio's Capex-to-Operating-Income for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Operating-Income	=	- Capital Expenditure	/	Operating Income
	=	- (0)	/	-11.29
	=	N/A

Third Harmonic Bio (NAS:THRD) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.

Third Harmonic Bio Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Third Harmonic Bio's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Third Harmonic Bio (Third Harmonic Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Third Harmonic Bio Inc (NAS:THRD) » Definitions » Capex-to-Operating-Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

1700 Montgomery Street, Suite 210, San Francisco, CA, USA, 94111

Website

https://www.thirdharmonicbio.com

Third Harmonic Bio Inc is a clinical-stage company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases.. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.

Executives

Julie Person	officer: Chief Administrative Officer	C/O THIRD HARMONIC BIO, INC., 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Edward R. Conner	officer: Chief Medical Officer	501 CANAL BLVD., POINT RICHMOND TECH CENTER, RICHMOND CA 94804
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il	10 percent owner	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Ii Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Inc/il	10 percent owner	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Orbimed Advisors Llc	director, 10 percent owner	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
David P Bonita	director, 10 percent owner	C/O ORBIMED ADVISORS LLC, 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139